JP2019536462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536462A5 JP2019536462A5 JP2019530105A JP2019530105A JP2019536462A5 JP 2019536462 A5 JP2019536462 A5 JP 2019536462A5 JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019536462 A5 JP2019536462 A5 JP 2019536462A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- genome editing
- cas9 protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 90
- 108020004707 nucleic acids Proteins 0.000 claims 65
- 102000039446 nucleic acids Human genes 0.000 claims 65
- 108091033409 CRISPR Proteins 0.000 claims 58
- 238000010362 genome editing Methods 0.000 claims 40
- 150000001413 amino acids Chemical class 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 108020005004 Guide RNA Proteins 0.000 claims 27
- 235000018102 proteins Nutrition 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 24
- 235000001014 amino acid Nutrition 0.000 claims 24
- 238000003780 insertion Methods 0.000 claims 22
- 230000037431 insertion Effects 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 230000001052 transient effect Effects 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 101710163270 Nuclease Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 101000897880 Spiroplasma virus SpV1-R8A2 B Putative capsid protein ORF9 Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000010363 gene targeting Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 230000010474 transient expression Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022208855A JP2023052089A (ja) | 2016-12-05 | 2022-12-26 | 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430154P | 2016-12-05 | 2016-12-05 | |
| US62/430,154 | 2016-12-05 | ||
| US201762503640P | 2017-05-09 | 2017-05-09 | |
| US62/503,640 | 2017-05-09 | ||
| PCT/US2017/064720 WO2018106693A1 (en) | 2016-12-05 | 2017-12-05 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022208855A Division JP2023052089A (ja) | 2016-12-05 | 2022-12-26 | 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536462A JP2019536462A (ja) | 2019-12-19 |
| JP2019536462A5 true JP2019536462A5 (enExample) | 2021-01-21 |
| JP7272952B2 JP7272952B2 (ja) | 2023-05-12 |
Family
ID=60972337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530105A Active JP7272952B2 (ja) | 2016-12-05 | 2017-12-05 | 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 |
| JP2022208855A Withdrawn JP2023052089A (ja) | 2016-12-05 | 2022-12-26 | 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022208855A Withdrawn JP2023052089A (ja) | 2016-12-05 | 2022-12-26 | 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9963719B1 (enExample) |
| EP (1) | EP3548614A1 (enExample) |
| JP (2) | JP7272952B2 (enExample) |
| KR (1) | KR102604903B1 (enExample) |
| CN (1) | CN110168084A (enExample) |
| AU (1) | AU2017373797B2 (enExample) |
| CA (1) | CA3046076A1 (enExample) |
| MX (2) | MX2019006475A (enExample) |
| WO (1) | WO2018106693A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230054509A (ko) | 2013-11-07 | 2023-04-24 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
| CA3001711A1 (en) * | 2015-10-30 | 2017-05-04 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US20190153440A1 (en) | 2017-11-21 | 2019-05-23 | Casebia Therapeutics Llp | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| WO2019118875A1 (en) * | 2017-12-15 | 2019-06-20 | Ou Li | Crispr-mediated genome editing with vectors |
| CA3104856A1 (en) | 2018-06-29 | 2020-01-02 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| WO2020055748A1 (en) * | 2018-09-10 | 2020-03-19 | The Regents Of The University Of California | Modulators of cas9 polypeptides and methods of use thereof |
| WO2020176552A1 (en) | 2019-02-25 | 2020-09-03 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| WO2020186059A2 (en) * | 2019-03-12 | 2020-09-17 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
| WO2020264254A1 (en) * | 2019-06-28 | 2020-12-30 | Crispr Therapeutics Ag | Materials and methods for controlling gene editing |
| WO2021053582A1 (en) * | 2019-09-18 | 2021-03-25 | Crispr Therapeutics Ag | All-in-one self inactivating crispr vectors |
| WO2021062201A1 (en) * | 2019-09-25 | 2021-04-01 | Spotlight Therapeutics | Compositions and methods for nucleoprotein targeting and expression |
| US20230203220A1 (en) * | 2020-05-29 | 2023-06-29 | Regents Of The University Of Minnesota | Copolymers for intracellular therapeutic nucleic acid payload delivery |
| CA3200815A1 (en) * | 2020-12-03 | 2022-06-09 | Benjamin OAKES | Compositions and methods for the targeting of bcl11a |
| WO2022221741A1 (en) | 2021-04-16 | 2022-10-20 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| WO2025179057A1 (en) * | 2024-02-21 | 2025-08-28 | The Regents Of The University Of California | In vivo modification of cell genomes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230054509A (ko) | 2013-11-07 | 2023-04-24 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
| SG10201804973TA (en) * | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders |
| EP3553176A1 (en) | 2014-03-10 | 2019-10-16 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| AU2015342749B2 (en) | 2014-11-07 | 2022-01-27 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
| KR102598856B1 (ko) * | 2015-03-03 | 2023-11-07 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| WO2016176404A1 (en) * | 2015-04-30 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Methods and kits for cloning-free genome editing |
| US20180291372A1 (en) * | 2015-05-14 | 2018-10-11 | Massachusetts Institute Of Technology | Self-targeting genome editing system |
| CN107849547B (zh) | 2015-05-16 | 2022-04-19 | 建新公司 | 深内含子突变的基因编辑 |
| US11530421B2 (en) | 2016-02-01 | 2022-12-20 | The Regents Of The University Of California | Self-inactivating endonuclease-encoding nucleic acids and methods of using the same |
| WO2017173004A1 (en) * | 2016-03-30 | 2017-10-05 | Mikuni Takayasu | A method for in vivo precise genome editing |
-
2017
- 2017-12-05 CA CA3046076A patent/CA3046076A1/en active Pending
- 2017-12-05 WO PCT/US2017/064720 patent/WO2018106693A1/en not_active Ceased
- 2017-12-05 KR KR1020197019386A patent/KR102604903B1/ko active Active
- 2017-12-05 AU AU2017373797A patent/AU2017373797B2/en active Active
- 2017-12-05 MX MX2019006475A patent/MX2019006475A/es unknown
- 2017-12-05 EP EP17829373.4A patent/EP3548614A1/en active Pending
- 2017-12-05 US US15/832,567 patent/US9963719B1/en active Active
- 2017-12-05 CN CN201780082711.XA patent/CN110168084A/zh active Pending
- 2017-12-05 JP JP2019530105A patent/JP7272952B2/ja active Active
-
2018
- 2018-03-23 US US15/934,750 patent/US10006054B1/en active Active
- 2018-05-15 US US15/980,450 patent/US10494649B2/en active Active
-
2019
- 2019-06-03 MX MX2024002327A patent/MX2024002327A/es unknown
- 2019-10-29 US US16/666,982 patent/US11028411B2/en active Active
-
2021
- 2021-05-27 US US17/332,764 patent/US11692205B2/en active Active
-
2022
- 2022-12-26 JP JP2022208855A patent/JP2023052089A/ja not_active Withdrawn
-
2023
- 2023-05-12 US US18/316,880 patent/US12264331B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536462A5 (enExample) | ||
| BR112021012665A2 (pt) | Polipeptídeos úteis para edição de genes e métodos de uso | |
| JP2021176301A (ja) | 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系 | |
| BRPI0612273A2 (pt) | anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade | |
| US20200340012A1 (en) | Crispr-cas genome engineering via a modular aav delivery system | |
| CN111757889A (zh) | 新型CRISPR/Cas12f酶和系统 | |
| JP2022529329A (ja) | 人工的に構築されたrna編集酵素による部位特異的rna編集および関連使用 | |
| ZA202304237B (en) | Dna modifying enzymes and active fragments and variants thereof and methods of use | |
| JP2019526248A5 (enExample) | ||
| JP2017513479A5 (enExample) | ||
| JP2019531068A5 (enExample) | ||
| EA201071323A1 (ru) | Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения | |
| JP2018534950A5 (enExample) | ||
| IL309801B1 (en) | Using nucleosome interacting protein domains to enhance targeted genome modification | |
| NO20081233L (no) | Albumin fusjonsproteiner | |
| JP2017018125A5 (enExample) | ||
| KR20160059994A (ko) | 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법 | |
| JP2018537087A5 (enExample) | ||
| ATE443074T1 (de) | Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren | |
| JP2015517803A5 (enExample) | ||
| WO2005080556A3 (en) | Virus purification methods | |
| JP2015532654A5 (enExample) | ||
| WO2005003296A3 (en) | Albumin fusion proteins | |
| DE602005016712D1 (de) | Rter dna | |
| ZA200007403B (en) | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals. |